Research programme: Dual-Affinity Re-Targeting anticancer therapeutics - MacroGenics

Drug Profile

Research programme: Dual-Affinity Re-Targeting anticancer therapeutics - MacroGenics

Alternative Names: 5T4 x CD3 DART; DART candidates - MacroGenics/Pfizer; DART Oncology; EphA2xCD3 DART; IL1Ra2xCD3 DART; JNJ-9383; MGD 015; MGD 019; MGD-15; PD-1 x CTLA-4 bispecific DART molecule; ROR1xCD3 DART

Latest Information Update: 28 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Bispecific antibodies; Proteins
  • Mechanism of Action CD3 antigen modulators; Interleukin 13 receptor modulators; Receptor tyrosine kinase-like orphan receptor modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Nov 2017 MacroGenics announces intention to submit IND application to the US FDA for MGD 019 in Cancer in 2018
  • 31 Aug 2017 Janssen plans a first-in-human phase I trial of MGD 015 for Cancer in 2018
  • 01 Apr 2017 Pharmacokinetics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top